With the first authorized generics entering the GLP-1 market this quarter, retail pharmacies are renegotiating contracts and rebates.
Pricing analysts expect monthly out-of-pocket costs to drop meaningfully by year end, though supply remains constrained.
Employers and PBMs are re-evaluating formularies as the weight-loss indication expands coverage debates.
